Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus

Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus

Background: To evaluate the immunogenicity and safety of the COVID-19 vaccine (Vero cell), inactivated, in a population aged ≥60 years with hypertension or(/and) diabetes mellitus. Methods: A total of 1440 participants were enrolled and divided into four groups, 330 in the hypertension group, 330 in...

Full description

Bibliographic Details
Main Authors: Yuntao Zhang, Haiping Chen, Jun Lv, Tao Huang, Ruizhi Zhang, Dongjuan Zhang, Linyun Luo, Sheng Wei, Xiaoqin Liu, Shangxiao Zhang, Qiuyue Mu, Rongdong Huang, Jiao Huang, Yanhui Xiao, Yunkai Yang, Yuting Han, Hao Gong, Qinghu Guan, Fangqin Xie, Hui Wang, Liming Li, Xiaoming Yang
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Vaccines
Subjects:
COVID-19 vaccine (Vero cell)
inactivated
elderly hypertensive population
elderly diabetic population
safety
immunogenicity
Online Access:https://www.mdpi.com/2076-393X/10/7/1020

Internet

https://www.mdpi.com/2076-393X/10/7/1020

Similar Items